Biologically active, hemagglutinin from type A
An isolated, biologically active 33 kDa hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.
1. A composition consisting essentially of purified, biologically active hemagglutinin-33 polypeptide (Hn-33) from type A Clostridium botulinum , an isolated and purified clostridial neurotoxin polypeptide that inhibits neurotransmitter release from a presynaptic membrane of a neurosensory junction and has protease activity, and optionally a pharmaceutical carrier suitable for administration to an animal, wherein the Hn-33 polypeptide enhances the protease activity of the clostridial neurotoxin polypeptide.
2. The composition of claim 1 , wherein the neurotoxin is selected from the group consisting of type A botulinum neurotoxin, type E botulinum neurotoxin, and tetanus toxin.
3. The composition of claim 1 , wherein the neurotoxin is type A botulinum neurotoxin.
4. The composition of claim 1 , wherein the pharmaceutical carrier is an adjuvant.
5. The composition of claim 1 , wherein the pharmaceutical carrier is selected from the group consisting of polysorbates, ethanol, starch, and glycerin.
6. The composition of claim 1 , wherein the biological activity of the Hn-33 comprises hemagglutination and the ability to protect the neurotoxin polypeptide from degradation in the gastrointestinal tract.